My goal in this letter is to begin to reconcile one of the most divisive and important debates in healthcare and nutrition today: the role of cholesterol in heart disease.

Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according ...

Background and rationaleIrritable bowel syndrome (IBS), a core disorder of gut–brain interaction, remains one of the most common and heterogeneous ...